2026年6月最新影响因子数据已更新，欢迎查询使用。如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
| 热门AI工具： |
论文引言生成
New
AI 写作痕迹检测
Hot
学术改写降重
论文摘要生成
参考文献挖掘工具
审稿意见辅助撰写
|
查看更多AI工具 >> |
| 近期推荐： | 热 Wiley 2026暑期线上学习营 | 报名正式开启！ | 新 Springer Nature生物医学与生命科学资源合集 | 附免费书单 | 热 全流程投稿协助套餐服务 |
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | Journal of Thoracic Oncology J THORAC ONCOL （此期刊被最新的JCR期刊SCIE收录） LetPub评分 9.2
50人评分
我要评分
声誉 9.9 影响力 8.6 速度 9.4 | |||||||||||||||||||||
| 期刊ISSN | 1556-0864 | 安装APP，查看期刊最新消息
| ||||||||||||||||||||
| E-ISSN | 1556-1380 | |||||||||||||||||||||
| 2025-2026最新IF （数据来源于网友提供） | 注册或登录后，查看IF | |||||||||||||||||||||
| 实时影响因子 | 截止2026年5月06日：22.69 | |||||||||||||||||||||
| 2025-2026自引率 | 4.3%点击查看自引率趋势图 | |||||||||||||||||||||
| 五年IF （数据来源于网友提供） | 22.304数据由网友[pixelmaple466]收集提供 | |||||||||||||||||||||
| h-index | 113 | |||||||||||||||||||||
| CiteScore （ 2026年6月最新版） |
| |||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||
| 期刊官方网站 | http://www.jto.org/ | |||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||
| 期刊投稿网址 | https://www.editorialmanager.com/JTO | |||||||||||||||||||||
| 该期刊中国学者近期发文 - New | First-Line Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Extensive-Stage SCLC: A Long-Term Survival and Programmed Death-Ligand 1 Subgroup Analysis From the Randomized, Phase 3 RATIONALE-312 Trial Author: Fan, Yun; Zhao, Yanqiu; Huang, Dingzhi; Zhao, Jun; Qin, Tai; He, Wanyu; Chen, Chenqi; Sun, Pu; Naicker, Kirsha; Song, Yong Journal: JOURNAL OF THORACIC ONCOLOGY. 2026; Vol. 21, Issue 6, pp. -. DOI: 10.1016/j.jtho.2026.103655 Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial Author: Novello, Silvia; Spigel, David R.; Fang, Jian; Chen, Yuanbin; Zenke, Yoshitaka; Lee, Ki Hyeong; Navarro, Alejandro; Buchmeier, Eva Lotte; Chang, John Wen-Cheng; Shiraishi, Yoshimasa; Ozguroglu, Mustafa; Kim, Yu Jung; Hoa, Nguyen Thi Thai; Hashemi, Sayed M. S.; Chiang, Anne C.; Turner, Ralph; Mann, Helen; Olivo, Yuka; Jiang, Haiyi; Senan, Suresh Journal: JOURNAL OF THORACIC ONCOLOGY. 2026; Vol. 21, Issue 6, pp. -. DOI: 10.1016/j.jtho.2026.103564 First Results from the COCOON Treatment Substudy in Managing Moderate to Severe Dermatologic Adverse Events in Participants with EGFR-mutated Advanced NSCLC Treated with First-line Amivantamab-Lazertinib Author: Spira, Alexander I.; Sauder, Maxwell B.; Feldman, Jill; Smith, Janellen; Girard, Nicolas; Li, Weimin; Bozorgmehr, Farastuk; Mak, Milena; Romero, Tonatiuh; Xia, Yichuan; Sheng, Shubin; Nematian-Samani, Mehregan; Simoes, Jairo; Wildgust, Mark; Cho, Byoung Chul Journal: JOURNAL OF THORACIC ONCOLOGY. 2026; Vol. 21, Issue 5, pp. -. DOI: Phase 1b/2 trial of BNT324/DB-1311 (B7H3 ADC) with Pumitamig (BNT327; PD-L1 x VEGF-A bsAb) in Lung Cancer (SCLC or NSCLC): BNT324-01 Trial in Progress Author: Schoenfeld, Adam; Spira, Alexander; Lisberg, Aaron E.; Gutierrez, Martin E.; Sankhala, Kamlesh; Byrne, Margaret; Reckamp, Karen L.; Qin, Angel; Marron, Thomas U.; Konduri, Kartik; Richards, Donald A.; Paschold, John; Layman, Clifton; Schenk, Erin L.; Parikh, Kaushal; Lou, Yanyan; Ernani, Vinicius; Adjei, Alex; Altan, Mehmet; Qiu, Yang; Fang, Hannah; Mu, Hua; Pinho, Michael; Reed, Troy; Soland, Melisa; Tibes, Raoul; Tuereci, Oezlem; Sahin, Ugur; Paz-Ares, Luis Journal: JOURNAL OF THORACIC ONCOLOGY. 2026; Vol. 21, Issue 5, pp. -. DOI: | |||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足Journal of Thoracic Oncology的语言要求，还能让Journal of Thoracic Oncology编辑和审稿人得到更好的审稿体验，让稿件最大限度地被Journal of Thoracic Oncology编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||
| 通讯方式 | LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, USA, PA, 19106-3621 | |||||||||||||||||||||
| 出版商 | International Association for the Study of Lung Cancer | |||||||||||||||||||||
| 涉及的研究方向 | 医学-呼吸系统 | |||||||||||||||||||||
| 出版国家或地区 | UNITED STATES | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | Monthly | |||||||||||||||||||||
| 出版年份 | 2006 | |||||||||||||||||||||
| 年文章数 | 108点击查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 27.60% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 93.52% | |||||||||||||||||||||
| WOS期刊JCR分区 （ 2025-2026年最新版） | 注册或登录后，查看WOS分区等级 | |||||||||||||||||||||
| 期刊分区表预警名单 | 2026年03月发布的新锐学术版：不在预警名单中 2025年03月发布的2025版：不在预警名单中 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||
  | ||||||||||||||||||||||
| 《新锐期刊分区表》 （ 2026年3月发布） | 点击查看期刊分区表趋势图
| |||||||||||||||||||||
| 期刊分区表 （ 2025年3月升级版） |
| |||||||||||||||||||||
| 期刊分区表 （ 2023年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1556-0864%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 一般,3-6周 | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 较易 | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在Journal of Thoracic Oncology顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | First-Line Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Extensive-Stage SCLC: A Long-Term Survival and Programmed Death-Ligand 1 Subgroup Analysis From the Randomized, Phase 3 RATIONALE-312 Trial Author: Fan, Yun; Zhao, Yanqiu; Huang, Dingzhi; Zhao, Jun; Qin, Tai; He, Wanyu; Chen, Chenqi; Sun, Pu; Naicker, Kirsha; Song, Yong Journal: JOURNAL OF THORACIC ONCOLOGY. 2026; Vol. 21, Issue 6, pp. -. DOI: 10.1016/j.jtho.2026.103655 PubMed DOI |
| 2. | Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial Author: Novello, Silvia; Spigel, David R.; Fang, Jian; Chen, Yuanbin; Zenke, Yoshitaka; Lee, Ki Hyeong; Navarro, Alejandro; Buchmeier, Eva Lotte; Chang, John Wen-Cheng; Shiraishi, Yoshimasa; Ozguroglu, Mustafa; Kim, Yu Jung; Hoa, Nguyen Thi Thai; Hashemi, Sayed M. S.; Chiang, Anne C.; Turner, Ralph; Mann, Helen; Olivo, Yuka; Jiang, Haiyi; Senan, Suresh Journal: JOURNAL OF THORACIC ONCOLOGY. 2026; Vol. 21, Issue 6, pp. -. DOI: 10.1016/j.jtho.2026.103564 PubMed DOI |
| 3. | First Results from the COCOON Treatment Substudy in Managing Moderate to Severe Dermatologic Adverse Events in Participants with EGFR-mutated Advanced NSCLC Treated with First-line Amivantamab-Lazertinib Author: Spira, Alexander I.; Sauder, Maxwell B.; Feldman, Jill; Smith, Janellen; Girard, Nicolas; Li, Weimin; Bozorgmehr, Farastuk; Mak, Milena; Romero, Tonatiuh; Xia, Yichuan; Sheng, Shubin; Nematian-Samani, Mehregan; Simoes, Jairo; Wildgust, Mark; Cho, Byoung Chul Journal: JOURNAL OF THORACIC ONCOLOGY. 2026; Vol. 21, Issue 5, pp. -. DOI: |
| 4. | Phase 1b/2 trial of BNT324/DB-1311 (B7H3 ADC) with Pumitamig (BNT327; PD-L1 x VEGF-A bsAb) in Lung Cancer (SCLC or NSCLC): BNT324-01 Trial in Progress Author: Schoenfeld, Adam; Spira, Alexander; Lisberg, Aaron E.; Gutierrez, Martin E.; Sankhala, Kamlesh; Byrne, Margaret; Reckamp, Karen L.; Qin, Angel; Marron, Thomas U.; Konduri, Kartik; Richards, Donald A.; Paschold, John; Layman, Clifton; Schenk, Erin L.; Parikh, Kaushal; Lou, Yanyan; Ernani, Vinicius; Adjei, Alex; Altan, Mehmet; Qiu, Yang; Fang, Hannah; Mu, Hua; Pinho, Michael; Reed, Troy; Soland, Melisa; Tibes, Raoul; Tuereci, Oezlem; Sahin, Ugur; Paz-Ares, Luis Journal: JOURNAL OF THORACIC ONCOLOGY. 2026; Vol. 21, Issue 5, pp. -. DOI: |
| 5. | Long-Term Outcomes with Tepotinib for Clinically Relevant Subgroups of Patients with MET Exon 14 (METex14) Skipping NSCLC in the VISION Study: A ≥3-Year Follow-Up Author: Paik, Paul K.; Ferrara, Roberto; Felip, Enriqueta; Smit, Egbert F.; Veillon, Remi; Le, Xiuning; Mazieres, Julien; Cortot, Alexis B.; Raskin, Jo; Thomas, Michael; Reinmuth, Niels; Yang, James Chih-Hsin; Ahn, Myung-Ju; Zhao, Jun; Sakai, Hiroshi; Viteri, Santiago; Wu, Yi-Long; Bruns, Rolf; Johne, Andreas; Griesinger, Frank Journal: JOURNAL OF THORACIC ONCOLOGY. 2026; Vol. 21, Issue 5, pp. -. DOI: |
| 6. | Safety and Patient-Reported Outcomes with Tepotinib in Patients with METex14 Skipping NSCLC: >3-Years Follow-Up of VISION Author: Paik, Paul K.; Ferrara, Roberto; Veillon, Remi; Le, Xiuning; Smit, Egbert F.; Mazieres, Julien; Cortot, Alexis B.; Raskin, Jo; Thomas, Michael; Reinmuth, Niels; Yang, James Chih-Hsin; Ahn, Myung-Ju; Zhao, Jun; Griesinger, Frank; Viteri, Santiago; Velthuis, Erica; Pescott, Chris; Rolf, Andreas; Bruns, Rolf; Felip, Enriqueta Journal: JOURNAL OF THORACIC ONCOLOGY. 2026; Vol. 21, Issue 5, pp. -. DOI: |
| 7. | Tepotinib in Patients with MET Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC) From the VISION Study: ≥3-Year Follow-Up Outcomes Author: Paik, Paul K.; Veillon, Remi; Cortot, Alexis B.; Ferrara, Roberto; Felip, Enriqueta; Garassino, Marina Chiara; Le, Xiuning; Thomas, Michael; Sakai, Hiroshi; Smit, Egbert F.; Raskin, Jo; Viteri, Santiago; Yang, James Chih-Hsin; Ahn, Myung-Ju; Wu, Yi-Long; Zhao, Jun; Ghori, Vishal; Bruns, Rolf; Johne, Andreas; Mazieres, Julien Journal: JOURNAL OF THORACIC ONCOLOGY. 2026; Vol. 21, Issue 5, pp. -. DOI: |
| 8. | Outcomes with First-Line Adagrasib with Pembrolizumab in Patients With KRASG12C-Mutated Non-Small Cell Lung Cancer (NSCLC), Including Analysis by Programmed Death Ligand 1 (PD-L1) Expression, from the Phase 2 Portion of the KRYSTAL-7 Study Author: Garassino, Marina Chiara; Janne, Pasi A.; Theelen, Willemijn S. M. E.; Spira, Alexander I.; Laskin, Janessa J.; de Marinis, Filippo; Badin, Firas Benyamine; Boom, Lisenka; De La Rosa, Carlos Aguado; Chmielewska, Izabela; Felip, Enriqueta; Ostoros, Gyula; Jimenez-Kurlander, Lauren; Sachdeva, Archie; Hayati, Sheida; Vemula, Sai Vikram; Eccles, Laura; Lu, Shun Journal: JOURNAL OF THORACIC ONCOLOGY. 2026; Vol. 21, Issue 5, pp. -. DOI: |
| 9. | Phase 3 study of Plinabulin/Docetaxel vs. Docetaxel in 2L/3L EGFR Wild Type NSCLC (DUBLIN-3): Post PD-1 Progression and Brain Metastasis Analyses Author: Feinstein, Trevor; Han, Baohui; Shi, Yuankai; Cheng, Gongyan; Yao, Yu; Hu, Chunhong; Shi, Jianhua; Feng, Jifeng; Wu, Huijuan; Cheng, Ying; Guo, Qi-sen; Jie, Zhijun; Ye, Feng; Zhang, Yiping; Liu, Zhihua; Mao, Weidong; Zhang, Liangming; Lu, Junguo; Zhao, Jun; Bazhenova, Lyudmila; Ruiz, Jimmy; Kloecker, Goetz H.; Sujith, Kalmadi R.; Oliff, Ira A.; Wong, Matthew; Liu, Bin; Wu, Yanping; Huang, Lan; Sun, Yan Journal: JOURNAL OF THORACIC ONCOLOGY. 2026; Vol. 21, Issue 5, pp. -. DOI: |
| 10. | Segmentectomy Achieves Non-Inferior Survival Outcomes Compared to Lobectomy in Peripheral <3 cm Non-Small Cell Lung Cancer with Occult Lymph Node Metastases Author: Chen, Yuting; Wang, Jie; Ding, Xusheng; Liu, Chunnan; Yan, Yueren; Sun, Yifu; Yuan, Chongze; Zheng, Shanbo; Shao, Longlong; Pan, Yunjian; Li, Hang; Zhang, Yiliang; Luo, Xiaoyang; Zhang, Yawei; Xiang, Jiaqing; Hu, Hong; Chen, Haiquan; Sun, Yihua Journal: JOURNAL OF THORACIC ONCOLOGY. 2026; Vol. 21, Issue 5, pp. -. DOI: |
|
|
  | ||||||||||||||||
|
投稿状态统计： 我要评分： | ||||||||||||||||
| 投稿前担心稿件结构或语言不够规范？试试稿件自查工具，一键检测 >> | ||||||||||||||||
|
||||||||||||||||
同领域作者分享投稿经验：共46条 |
||||||||||||||||
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2026 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
投稿信 (Cover Letter) 模板
